Phoenix Tissue Repair Doses First Patient in Phase 1/2 Clinical Trial of PTR-01 (BBP-589) for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

02.22.2019

BridgeBio Pharma Closes $299.2 Million Financing Round to Support Its Efforts to Target Genetic Disease at the Source

01.23.2019

Eidos Therapeutics to Present at 37th Annual J.P. Morgan Healthcare Conference

01.02.2019

news

Catch up on news from BridgeBio and its companies and follow developments about the promising treatments in our pipeline. Follow us on LinkedIn and Twitter to keep up with all the latest news.

Links to an external site